# A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

> **NCT07481383** · PHASE1 · RECRUITING · sponsor: **Continuity Biosciences, LLC** · enrollment: 12 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma Non-resectable

## Interventions

- **COMBINATION_PRODUCT:** ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003)

## Key facts

- **NCT ID:** NCT07481383
- **Lead sponsor:** Continuity Biosciences, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-11
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481383, "A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07481383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*